Literature DB >> 21062997

Myocardial perfusion grade after late infarct artery recanalization is associated with global and regional left ventricular function at one year: analysis from the Total Occlusion Study of Canada-2.

Terje K Steigen1, Christopher E Buller, G B John Mancini, Vinod Jorapur, Warren J Cantor, James M Rankin, Boban Thomas, John G Webb, Shari S Kronsberg, Deborah J Atchison, Gervasio A Lamas, Judith S Hochman, Vladimír Džavík.   

Abstract

BACKGROUND: Whether myocardial perfusion grade (MPG) following late recanalization of infarct-related arteries (IRAs) predicts left ventricular (LV) function recovery beyond the acute phase of myocardial infarction (MI) is unknown. METHODS AND
RESULTS: The Total Occlusion Study of Canada-2 enrolled stable patients with a persistently occluded IRA beyond 24 hours and up to 28 days post-MI. We studied the relationship between the initial MPG and changes in LV function and volume as well as the change in MPG from immediate post-percutaneous coronary intervention (PCI) to 1 year in 139 PCI patients with thrombolysis in myocardial infarction grade 3 epicardial flow post-PCI and with paired values grouped into impaired or good MPG groups (MPG 0/1 or MPG 2/3). MPG 0/1 patients were more likely to have received thrombolytic therapy and to have a left anterior descending IRA. They had lower blood pressure and LV ejection fraction (LVEF) and a higher heart rate and systolic sphericity index at baseline. Changes in the MPG 0/1 and MPG 2/3 groups from baseline to 1 year were LVEF, 3.3±9.0% and 4.8±8.9% (P=0.42); LV end-systolic volume index (LVESVI), -1.1±9.2 and -4.7±12.3 mL/m(2) (P=0.25); LV end-diastolic volume index (LVEDVI), 0.08±19.1 and -2.4±22.2 mL/m(2) (P=0.67); and SDs/chord for infarct zone wall motion index (WMI), 0.38±0.70 and 0.84±1.11 (P=0.01). By covariate-adjusted analysis, post-PCI MPG 0/1 predicted lower WMI (P<0.001), lower LVEF (P<0.001), and higher LVESVI (P<0.01) but not LVEDVI at 1 year. Of the MPG 0/1 patients, 60% were MPG 2 or 3 at 1 year.
CONCLUSIONS: Preserved MPG is present in a high proportion of patients following late PCI of occluded IRAs post-MI. Poor MPG post-PCI frequently improves MPG over 1 year. MPG graded after IRA recanalization undertaken days to weeks post MI is associated with LV recovery, indicating that MPG determined in the subacute post-MI period remains a marker of viability. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00025766.

Entities:  

Mesh:

Year:  2010        PMID: 21062997      PMCID: PMC3640427          DOI: 10.1161/CIRCINTERVENTIONS.109.918722

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  25 in total

1.  Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs.

Authors:  C M Gibson; C P Cannon; S A Murphy; K A Ryan; R Mesley; S J Marble; C H McCabe; F Van De Werf; E Braunwald
Journal:  Circulation       Date:  2000-01-18       Impact factor: 29.690

2.  Volumetric intravascular ultrasound evidence that distal embolization during acute infarct intervention contributes to inadequate myocardial perfusion grade.

Authors:  Jun-ichi Kotani; Gary S Mintz; Jerzy Pregowski; Lukasz Kalinczuk; Augusto D Pichard; Lowell F Satler; William O Suddath; Ron Waksman; Neil J Weissman
Journal:  Am J Cardiol       Date:  2003-09-15       Impact factor: 2.778

3.  Advantages and applications of the centerline method for characterizing regional ventricular function.

Authors:  F H Sheehan; E L Bolson; H T Dodge; D G Mathey; J Schofer; H W Woo
Journal:  Circulation       Date:  1986-08       Impact factor: 29.690

4.  The use of single plane angiocardiograms for the calculation of left ventricular volume in man.

Authors:  H Sandler; H T Dodge
Journal:  Am Heart J       Date:  1968-03       Impact factor: 4.749

5.  The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone.

Authors:  James E Udelson; Camille A Pearte; Carey D Kimmelstiel; Mariusz Kruk; Joseph A Kufera; Sandra A Forman; Anna Teresinska; Bartosz Bychowiec; Jose Antonio Marin-Neto; Thomas Höchtl; Eric A Cohen; Paulo Caramori; Benita Busz-Papiez; Christopher Adlbrecht; Zygmunt P Sadowski; Witold Ruzyllo; Debra J Kinan; Gervasio A Lamas; Judith S Hochman
Journal:  Am Heart J       Date:  2011-03       Impact factor: 4.749

6.  Coronary flow velocity analysis during short term follow up after coronary reperfusion: use of transthoracic Doppler echocardiography to predict regional wall motion recovery in patients with acute myocardial infarction.

Authors:  T Hozumi; Y Kanzaki; Y Ueda; A Yamamuro; T Takagi; T Akasaka; S Homma; K Yoshida; J Yoshikawa
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

7.  Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction.

Authors:  C Michael Gibson; Sabina A Murphy; Ajay J Kirtane; Robert P Giugliano; Christopher P Cannon; Elliott M Antman; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2004-09-01       Impact factor: 24.094

8.  Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty.

Authors:  Giuseppe De Luca; Arnoud W J van 't Hof; Menko-Jan de Boer; Jan Paul Ottervanger; Jan C A Hoorntje; A T Marcel Gosselink; Jan-Henk E Dambrink; Felix Zijlstra; Harry Suryapranata
Journal:  Eur Heart J       Date:  2004-06       Impact factor: 29.983

9.  Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction.

Authors:  J P S Henriques; F Zijlstra; J P Ottervanger; M-J de Boer; A W J van 't Hof; J C A Hoorntje; H Suryapranata
Journal:  Eur Heart J       Date:  2002-07       Impact factor: 29.983

10.  Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first?

Authors:  R A Kloner; R E Rude; N Carlson; P R Maroko; L W DeBoer; E Braunwald
Journal:  Circulation       Date:  1980-11       Impact factor: 29.690

View more
  6 in total

1.  Microvascular perfusion in infarcted and remote myocardium after successful primary PCI: angiographic and CMR findings.

Authors:  Anne Bethke; Limalanathan Shanmuganathan; Geir Øystein Andersen; Jan Eritsland; David Swanson; Nils Einar Kløw; Pavel Hoffmann
Journal:  Eur Radiol       Date:  2018-07-06       Impact factor: 5.315

2.  The duration of early systolic lengthening may predict ischemia from scar tissue in patients with chronic coronary total occlusion lesions.

Authors:  Muzaffer Kahyaoglu; Cetin Gecmen; Ozkan Candan; Ibrahim Akin İzgi; Cevat Kirma
Journal:  Int J Cardiovasc Imaging       Date:  2019-05-11       Impact factor: 2.357

3.  Left Ventricular Unloading Using an Impella CP Improves Coronary Flow and Infarct Zone Perfusion in Ischemic Heart Failure.

Authors:  Shin Watanabe; Kenneth Fish; Jason C Kovacic; Olympia Bikou; Lauren Leonardson; Koichi Nomoto; Jaume Aguero; Navin K Kapur; Roger J Hajjar; Kiyotake Ishikawa
Journal:  J Am Heart Assoc       Date:  2018-03-07       Impact factor: 5.501

Review 4.  Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers.

Authors:  Alexander E Berezin; Alexander A Berezin
Journal:  Dis Markers       Date:  2020-06-12       Impact factor: 3.434

5.  Calculation of Coronary Angiographic Total Blush in Patients with Coronary Artery Disease and its Prognostic Implication.

Authors:  Jing-Jing Gai; Lu-Yue Gai; Jian-Jun Yan; Qin-Hua Jin
Journal:  Chin Med J (Engl)       Date:  2015-09-20       Impact factor: 2.628

Review 6.  Evaluation of donor heart for transplantation.

Authors:  Robert Tatum; Alexandros Briasoulis; Vakhtang Tchantchaleishvili; H Todd Massey
Journal:  Heart Fail Rev       Date:  2022-02-04       Impact factor: 4.654

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.